Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Stephen M. Ansell; Anne J. Novak; Steven Ziesmer; Tammy Price-Troska; Betsy Laplant; Stacey R. Dillon; Thomas E. Witzig

doi:10.1002/ajh.21328

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Stephen M. Ansell, Anne J. Novak, Steven Ziesmer, Tammy Price-Troska, Betsy Laplant, Stacey R. Dillon, Thomas E. Witzig

Hematology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

Original language	English (US)
Pages (from-to)	71-73
Number of pages	3
Journal	American journal of hematology
Volume	84
Issue number	2
DOIs	https://doi.org/10.1002/ajh.21328
State	Published - Feb 2009

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.21328

Cite this

@article{e3b5272c1d3040178c4d03a9fb2177dd,

title = "Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma",

abstract = "Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.",

author = "Ansell, {Stephen M.} and Novak, {Anne J.} and Steven Ziesmer and Tammy Price-Troska and Betsy Laplant and Dillon, {Stacey R.} and Witzig, {Thomas E.}",

year = "2009",

month = feb,

doi = "10.1002/ajh.21328",

language = "English (US)",

volume = "84",

pages = "71--73",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

AU - Ansell, Stephen M.

AU - Novak, Anne J.

AU - Ziesmer, Steven

AU - Price-Troska, Tammy

AU - Laplant, Betsy

AU - Dillon, Stacey R.

AU - Witzig, Thomas E.

PY - 2009/2

Y1 - 2009/2

N2 - Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

AB - Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

UR - http://www.scopus.com/inward/record.url?scp=59949089567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59949089567&partnerID=8YFLogxK

U2 - 10.1002/ajh.21328

DO - 10.1002/ajh.21328

M3 - Article

C2 - 19051265

AN - SCOPUS:59949089567

SN - 0361-8609

VL - 84

SP - 71

EP - 73

JO - American journal of hematology

JF - American journal of hematology

IS - 2

ER -

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this